PP-141 Predicting treatment response in hepatitis C virus infected patients: from gene to protein expression  by Chen, Limin et al.
S86 Poster Presentation – Hepatitis C
mal control group and HCV-related chronic hepatitis regarding
the HGFA H-score and TGF-β1 H-score.
Conclusions: Parallel expression of HGFA and TGF-β1 with the
grade of activity and stage of ﬁbrosis in HCV-related chronic hep-
atitis could make HGFA as an activity and regenerative marker.
PP-138 Screening and cloning of gene of hepatocyte
protein interacting with HCV NS5ATP4A protein
Lian-feng Zhang1, Jun Cheng*,2, Li-dong Chen3, Ji-chang Li 1,
Wei Liu. 1The First Afﬁliated Hospital of Zhengzhou University;
2Ditan Hospital, Beijing, China; 3The Second Peoples’ Hospital
of Jiaozuo
Objective: We screen proteins of hepatocyte protein interacting
with hepatitis C virus NS5ATP4A protein to clarify the signal
transduction pathway of HCV.
Methods: “Bait” plasmids of hepatitis C virus NS5ATP4A were
constructed. After verifying that hepatitis C virus NS5ATP4A pro-
tein could be steadily expressed in AH109 yeast strain, yeast-two
hybrid assay was performed by mating AH109 with Y187 that
pre-transformed with liver cDNA library plasmids pACT2, and the
diploidy yeast cells were plated on quadruple dropout (QDO)
medium and assayed for X-α-gal activity. Nineteen yeast colonies
that could grow on QDO and hadα-gal activity were obtained,
then the library plasmids were extracted and sequenced.
Results: 7 genes were screened out and one of them was un-
known gene. These genes were associated RNA synthesis, protein
translation, cell cycle and tumor immune.
Conclusion: NS5ATP4 binding proteins were successfully
screened,which offer new clues to the signal transduction path-
way of NS5ATP4A and the pathogenic mechanism of HCV.
PP-139 The evaluation of the hepatic ﬁbrosis and its
progression rate in chronic hepatitis C
Dana Damian*, Mircea Grigorescu, Teodor Zaharie. Third Medical
Clinic, Cluj Napoca, Romania
Aim: The evaluation of ﬁbrosis through Ishak and Metavir scoring
systems and it’s progression rate.
Methods: We studied 242 naïve patients with chronic hepatitis
C, admitted between 2003 and 2006, who performed liver biopsy
for diagnosis, being evaluated according two scoring systems.
The evaluation of the ﬁbrosis progression rate was performed
only in 55 patients with a previous history of transfusions, using
the ratio between the ﬁbrosis stage and the estimated infection
duration (years).
Results: The mild and moderate ﬁbrosis lesions predominated,
with a concordance between the scoring systems.
The mean ﬁbrosis index was signiﬁcantly larger in patients with
moderate/severe necroinﬂamatory lesions, irrespective of the
normal or increased AST or ALT levels.
The mean ﬁbrosis progression rate of 0.23±0.34 units/year ac-
cording to the Metavir system, and 0.32±0.51 units/year - Ishak
system.
The age at the time of infection and it’s estimated duration
correlate with the Metavir ﬁbrosis progression rate (p =0.000,
respectively p =0.001). The patients who have been infected
before the age of 40 and those with a duration of infection of less
than 20 years have a signiﬁcantly lower mean ﬁbrosis progression
rate.
Conclusions: 1. The mild and moderate ﬁbrosis predominated,
with equivalent results between the two scoring systems.
2. The severity of ﬁbrosis correlated with the age and the
increased AST or ALT levels.
3. The mean ﬁbrosis progression rate was 0.23±0.34 units/year in
the Metavir system, respectively 0.31±0.51 units/year in Ishak,
being correlated with the age at the moment of infection and it’s
estimated duration of evolution.
PP-140 The occult HCV infection
Dana Damian*, Mircea Grigorescu, Mircea Dan Grigorescu,
Teodor Zaharie. Third Medical Clinic, Cluj Napoca, Romania
Aim: evaluating the presence and localisation of the HCV anti-
gens (NS3, NS5, NS5A) in patients with chronic hepatitis C and
undetectable versus detectable serum HCV-RNA.
Methods: 93 patients with chronic hepatitis C were included in
the study, 55 with detectable viremia. Using immunohistochem-
ical techniques involving monoclonal and policlonal antibodies,
we analysed the presence, localisation and semiquantitative
grading of coloured cells.
Results: All untreated patients with detectable viremia pre-
sented hepatocyte expression of viral proteins, especially in the
hepatocyte cytoplasm and less in the nucleus. The untreated sub-
jects with undetectable viremia had similar detection rate as the
untreated patients with detectable viremia, 92.3% respectively
92.4% and 84.61% for NS3, NS5, NS5A.
In treated patients with undetectable viremia, the proportion
of positive results were comparable for NS3 (92%) but lower
for NS5 and NS5A (80% and 60%). The positive immunohisto-
chemical reaction was observed in fewer hepatocytes (< 30%),
with focal lobular distribution and mild/moderate intensity in
treated subjects with undetectable viremia, respectively moder-
ate/important in the rest of patients.
The patients with undetectable viremia were found to have cor-
relationships between the presence of NS3 and NS5 antigens and
the ﬁbrosis level. The presence of steatosis correlated with NS3
and NS5 only in untreated patients with undetectable viremia.
The portal space involvement was observed especially at
macrophages.
Conclusions: Identifying the presence of viral antigens in the
liver tissue in patients with undetectable viremia, who have
either received antiviral therapy or not, can bring into discussion
the occult HCV infection.
PP-141 Predicting treatment response in hepatitis C virus
infected patients: from gene to protein
expression
Limin Chen*,1, Jing Sun1, Maha Guindi 2, Jordan Feld1,
Jenny Heathcote1, Aled Edwards1, Ian McGilvray1. 1Uiversity of
Toronto, Toronto, Canada; 2University Health Network, Toronto,
Canada
Objectives: Chronic hepatitis C virus (CHC) infection is treated
with interferon/ribavirin, but only a subset of patients re-
spond. We previously reported that treatment nonresponders
have marked pre-treatment upregulation of a subset of inter-
feron stimulated genes (ISGs) in their livers, including ISG15
(Chen, et al. Gastroenterology 2005). Here, we study the source
of the ISG expression signature and uncover the cellular basis of
the phenotype through ISG15 and MxA protein expression.
Methods: ISG15 and MxA immunohistochemistry was performed
on a subset of 31 liver biopsies and the expression pattern was
correlated with response status.
Results: Using a simple histology scale scored from 0 to 3
(0: no staining in any cell, 3: staining in every cell), we
found signiﬁcantly more hepatocyte ISG15 expression in treat-
ment non-responders versus responders (2.4±0.6 vs 1.1±0.6,
p<0.0001), but less macrophage ISG15 staining (0.2±0.4 vs
0.8±0.6, p<0.005). MxA protein expression had a similar cell-
speciﬁc pattern of expression. Treatment response was linked
to cell-speciﬁc activation patterns: ISG15 and MxA protein up-
regulation was more pronounced in hepatocytes in treatment
nonresponders, but in Kuppfer cells in responders.
Conclusions: Our previously deﬁned differential gene expression
pattern in the livers of HCV responders and nonresponders is
driven by activation of different cell types: hepatocytes in treat-
ment nonresponders, and macrophages in treatment responders.
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This ﬁnding will help to develop diagnostic tools that can be used
to predict treatment response before interferon-based ther-
apy. It also provides insights into the molecular mechanism of
interferon resistance in HCV infected patients.
PP-142 The predictive value of viral response during
treatment to sustained viral response obtaining
in chronic hepatitis C personalized treatment
programs
Ming-hui Li *, Yao Xie, Li-jun Chen, Guo-hua Qiu, Yao Lu,
Dao-zhen Xu. Deparment of Liver Diseases, Ditan Hospital,
Beijing, PR China
The antiviral effects of interferon in chronic hepatitis C is inﬂu-
enced by many factors, among which the personalized interferon
and RBV dose, treatment course were the most important. The
viral response during treatment was the composite expression of
factors associated with treatment effects, and the very impor-
tant predictive for sustained obtaining.
In this paper, the enrolled patients with chronic hepatitis C, were
given the intensive treatment doses of interferon and ribavin
according to their basic clinical condition. in the treatment of
0, 4, 12, 24 weeks, the end of threatment and 24 weeks after
treatment stop, the serum HCV RNA were ditermined, and ac-
cording the viral response on-treatment the individuation cours
was given, and the value of viral responses, including rapid viral
response, (RVR), deﬁneted serum HCV RNA undetectable at 4
week, and complete early viral response (cEVR), serum virus
undetectable at 4 week, on-treatment was anylised predictive
for SVR obtained. Given the personalized therapeutic program,
84.2% of patients obtained RVR, among which 90.7% obtained
SVR. The RVR was not associated with HCV genotypes (χ2=6.00,
p=0.112), but signiﬁcantly with serum HCV RNA load baseline
(t=2.15, p=0.034), which in RVR was lg 5.883±1.246 copies/ml,
and lg 6.502±0.693 copies/ml in non-RVR. The RVR rate (87.8%)
of vaive patients interferonα-2a was higher than that of re-
treatment patients (65.0%) signiﬁcantly in pegylated interferon
treatment group (χ2=4.651, p=0.031). 92.4% (122/132) of pa-
tients obtained cEVR, those in pegylated interferon α-2a 180mg,
135mg and standard interferon group were 90.5%, 95.0% and
90.4%, and the difference among the three groups was not signif-
icant difference (χ2 = 0.981, p = 0.640). The SVR rate of patients
with cEVR was SVR was 90.8% (108/119), which was signiﬁcantly
higher than that, 55.56% (5/9), of patients with no cEVR rate
(Fisher’s exact test, p = 0.007). The cEVR rate between naïve and
retreatment patients was not difference (χ2=1.993, p=0.158),
which were 94.7% (90/95) and 85% (17/20) respectively, and the
difference of cEVR rate between genotpye 1 and non 1 group was
not signiﬁcance aslo (χ2=6.000, p=0.112), 91.22% (52/57) and
96.29% (26/27) respectively. This study showed that, RVR and
cEVR were signiﬁcantly related to SVR, and personality therapy
can improve the obtaining probability of RVR, cEVR and the SVR.
According to the clinical characteristics of patients, given inten-
sive doses of interferon and RBV, adjusted drug dose timely, and
extended treatment of HCV RNA-negative course based on pa-
tient response were important in chronic hepatitis C personalized
treatment.
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PP-143 APOBEC3G/B/F mRNA levels in PBMC of
HIV-infected patients and there correlation with
CD4+ T cell counts
Zhenyan Wang*,1,2, Hongzhou Lu2. 1Shanghai Public Health
Clinical Center; 2Fudan University
Background: Apolipoprotein B mRNA-editing enzyme, catalytic
polypeptide-like 3G/B/F(hA3G/B/F) showed anti-HIV activity in
extro, though there correlation with HIV disease progression is
not clear. Our aim is to quantitative investigate hA3G/B/F mRNA
levels in HIV-infected patients, then analyze there correlation
with CD4 counts.
Methods: Peripheral blood samples were collected from 21 HIV-
infected subjects not taking antiretroviral therapy (ART) and
21 HIV-infected subjects receiving ART, and 10 HIV-uninfected
controls.hA3G/B/F mRNA levels in PBMC were determined by
real-time ﬂuorescent quantitative PCR. Flow cytometry was used
to detect CD4 counts.
Results: There was no correlation between hA3G/B/F mRNA lev-
els and CD4 counts in either ART+ or ART- HIV-infected subjects.
hA3G mRNA level in HIV-infected subjects was lower than that
in HIV-uninfected controls (P<0.05), but no statistical difference
between ART+ and ART- groups (P>0.05). However, signiﬁcant
difference were found in hA3B/F mRNA levels between the three
groups (P<0.05): ART- HIV-infected subjects < ART+ HIV-infected
subjects < HIV-uninfected controls. hA3G/B/F mRNA levels were
positively correlated with one another in ART+ HIV-infected sub-
jects and HIV-uninfected controls, while not in ART- HIV-infected
subjects.
Conclusion: hA3G/B/F gene expression levels do not directly
correlate with HIV-1 disease progression. Host hA3G/B/F expres-
sion levels tend to decrease after HIV-1 infection, and ART may
elevate hA3B/F mRNA levels, but not for hA3G. The function of
hA3 family proteins in anti-HIV infection needs further study.
PP-144 Substitution treatment implementations in
Ukraine – impact on HIV prevalence
Dmitry Metlitsky*. All-Ukrainian Network of PLWHAs
Substitution treatment is recognized as effective part of biomed-
ical preventions and one of the main tools of HIV/AIDS epidemic
control among IDU’s. ST admitted as essential choice for IDU if
ones fail rehabilitation programs.
Although Ukraine has the highest HIV-prevalence in Eastern-
Europe regions (large portion of vulnerable populations consists
of IDU’s), ST implementation was under the major focus of donors
(Global Fund, Sunrise, Clinton Foundation).
By the reason ST was quit new activity for Ukraine vertical model
of implementation – from center to regions were chosen. It
meant that advocacy for needed decrees from Ministry of Health,
drugs regulation authorities was made on the national level.
Then a number of regional sites were opened.
In result regional medical authorities asked for help in meeting
of requirement in ST sites, they started to participate in project
competitions for sites ﬁnancing, they realized advantages of new
model of work with IDU’s.
As conclusion it should be mentioned that central advocacy work
saved time and made regional implementation of program much
easier. As the second phase – regions begun plan their activities
accordingly needs of the regions. Governmental authorities were
satisﬁed with decreasing of HIV transmission among IDU, more
social reliability of patients and lower mortality rate among
them.
Statistic data is available.
PP-145 P53 and mitochondrial toxicity induced by AZT
Dexi Chen*, Yu Sun, Yasong Wu, Hao Wu, Xinyue Chen. Beijing
You An Hospital Capital Medicla University
The mitochondrial toxicity of nucleoside reverse transcriptase
inhibitors (NRTIs) is due to the inhibition of mitochondrial DNA
(mtDNA) polymerase γ (Pol γ), resulting in a blockade of mtDNA
replication and subsequent disruption of cellular energetics1.
Previous study showed that p53 play a direct role through in-
teraction with DNA Pol γ or mitochondrial transcription factor
